The efficacy and safety of tislelizumab combined with weekly nab-paclitaxel, carboplatin, and cetuximab as first-line treatment for recurrent or metastatic head and neck squamous cell carcinoma: a real-world study.

ABSTRACT:

Background

Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) face poor prognosis. This study evaluated the efficacy and safety of a novel first-line regimen combining tislelizumab, nab-paclitaxel, carboplatin, and cetuximab (TPCE) in R/M-HNSCC.

Methods

In this retrospective study, 39 patients with R/M-HNSCC received tislelizumab (200 mg, day 1), nab-paclitaxel (125 mg/m², days 1, 8), carboplatin (AUC = 2, days 1, 8), and cetuximab (400 mg/m² loading dose, then 250 mg/m² weekly, day 1) every 21 days for up to six cycles. Patients achieving stable disease or better continued maintenance therapy with cetuximab and tislelizumab until disease progression or unacceptable toxicity. The primary endpoint was objec

SUBMITTER: Ouyang Z 

PROVIDER: S-EPMC12827551 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature